UCB S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UCBJF research report →
Companywww.ucb.com
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus.
- CEO
- Jean-Christophe Tellier
- IPO
- 2008
- Employees
- 9,052
- HQ
- Brussels, BE
Price Chart
Valuation
- Market Cap
- $53.60B
- P/E
- 29.10
- P/S
- 5.87
- P/B
- 4.17
- EV/EBITDA
- 19.78
- Div Yield
- 0.43%
Profitability
- Gross Margin
- 74.29%
- Op Margin
- 25.32%
- Net Margin
- 20.13%
- ROE
- 15.16%
- ROIC
- 12.13%
Growth & Income
- Revenue
- $7.74B · 25.78%
- Net Income
- $1.56B · 46.24%
- EPS
- $8.20 · 46.17%
- Op Income
- $2.01B
- FCF YoY
- 104.49%
Performance & Tape
- 52W High
- $345.39
- 52W Low
- $175.75
- 50D MA
- $295.52
- 200D MA
- $283.28
- Beta
- 0.17
- Avg Volume
- 759
Get TickerSpark's AI analysis on UCBJF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our UCBJF Coverage
We haven't published any research on UCBJF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate UCBJF Report →